Cancer World Magazine
  • About the Journal
    • Editorial Team
    • Leadership and Management
    • Journal staff
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
NEWSLETTER  |  PRINT VERSION
Facebook
Twitter
LinkedIn
Cancer World Magazine
Cancer World Magazine
  • About the Journal
    • Editorial Team
    • Leadership and Management
    • Journal staff
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine > News > Gut microbiome positively influences abiraterone response in prostate cancer
  • News

Gut microbiome positively influences abiraterone response in prostate cancer

  • 5 November 2020
  • Janet Fricker
gut microbiome and Abiraterone response in prostate cancer
Total
0
Shares
0
0
0
0
0
Abiraterone acetate (AA), an agent used in castrate-resistant prostate cancer, promotes a shift towards health-associated, anti-inflammatory gut commensal bacteria, finds a study in Nature Communications. “These findings clearly demonstrate that the gut microbiome is playing a role in treatment response,” says Jeremy Burton, the study lead investigator from the University of Western Ontario, London, Canada. The study, the researchers believe, represents just one example of the influence the gut microbiome is likely to be having on responses to medications. AA is used to treat prostate cancer that has become resistant to other treatments, works by inhibiting CYP17A1, the rate-limiting enzyme implicated in androgen biosynthesis. Notably, AA is a poorly absorbed oral agent, resulting in exposure of patients gastrointestinal microbiota to unusual high levels of the drug. “While it has long been a mystery why abiraterone acetate is so effective, our team wondered if the gut microbiome plays a role,” says Burton. Investigators collected and analysed stool samples from 68 patients with prostate cancer, including those not receiving any active treatment (n=33), those receiving traditional androgen deprivation therapy (ADT; n =21), and those receiving both ADT and treatment with orally administered AA (n=14). Results of 16S rRNA gene sequencing revealed that a considerable enrichment of Akkermansia muciniphila (A. muciniphila) in samples from patients who received ADT plus AA (95%CI 0.094−2.436%) compared to ADT alone (95%CI 0.031−0.304%) and patients not receiving active treatment (controls) (95%CI 0.035−0.565%). Using an in vitro simulated human gut microbiota model (to exclude possibilities of immune involvement) the team showed exposure to AA (250 mg/day) for 6 consecutive days, delivered a 130-fold increase in relative abundance of A. muciniphila levels within 24 hours. A. muciniphila is a commensal bacteria known to be associated with good health and to have anti-inflammatory effects. The team also observed both AA and traditional androgen deprivation therapies demonstrated a decreased relative abundance of the androgen-utilising and pro-inflammatory Corynebacterium spp compared to the control group. “These results suggest that depletion of circulating androgen levels via systemic ADT may indirectly reduce host colonization by testosterone-metabolizing species,” write the authors. The study further showed increases in A. muciniphila led to an increase in production of vitamin K2. Interestingly, vitamin K2 is a prospective anti-cancer agent that has been shown to target castrate-resistant prostate cancer in vitro and inhibit androgen-dependent and androgen-independent tumour growth in mouse models. Additionally, a large European prospective study demonstrated that dietary intakes of vitamin K2 were inversely associated with prostate cancer. “Our results suggest that the efficacy of AA may be imparted through its ability to increase microbially synthesized vitamin K2 in men with prostate cancer via specific interactions with the key symbiont, A. muciniphila,” write the authors.  The latest findings, they add, build on previous studies demonstrating that A. muciniphila improves the efficacy of checkpoint inhibitors.
Download Pdf
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • abiraterone
  • commensal bacteria
  • Microbiome
  • prostate cancer
  • vitamin K12
Janet Fricker

Previous Article
  • Interviews to the Expert

Cervical cancer: the SENTIX trial

  • 3 November 2020
  • Alberto Costa
View Post
Next Article
  • News

Roundtable ‘grasps nettle’ on European cancer inequalities

  • 6 November 2020
  • Janet Fricker
View Post
You May Also Like
View Post
  • News

Coffee may protect against prostate cancer

  • Janet Fricker
  • 20 January 2021
View Post
  • News

Financial burden on older adults with advanced cancer worsens quality of life

  • Janet Fricker
  • 15 January 2021
View Post
  • News

Integrated imaging opens the way for virtual biopsies

  • Janet Fricker
  • 15 January 2021
View Post
  • News

Cancer survivors at greater risk of subsequent primary cancers

  • Janet Fricker
  • 30 December 2020
View Post
  • News

Immunotherapy cardiotoxicity higher than previously estimated

  • Janet Fricker
  • 24 December 2020
NHS cancer screening blood test
View Post
  • News

NHS England’s pilot of cancer screening blood test raises questions

  • Janet Fricker
  • 21 December 2020
View Post
  • News

Building back cancer services after Covid-19: European Cancer Organisation plan

  • Janet Fricker
  • 2 December 2020
View Post
  • News

Prolonged ADT use in prostate cancer increases CV mortality: A need for cardiovascular protection

  • Janet Fricker
  • 27 November 2020
1 comment
  1. yAntonio says:
    6 November 2020 at 17:08

    tes commento

    Reply

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

search
or search in Cancer World archive
Latest news
  • Coffee may protect against prostate cancer
    • 20 January 2021
  • Financial burden on older adults with advanced cancer worsens quality of life
    • 15 January 2021
  • Integrated imaging opens the way for virtual biopsies
    • 15 January 2021
  • Cancer survivors at greater risk of subsequent primary cancers
    • 30 December 2020
  • Immunotherapy cardiotoxicity higher than previously estimated
    • 24 December 2020
Latest printed issue
Article
  • Berlin pilot project brings precision care to the peripheries
    • 15 January 2021
  • Highlights of 2020 American Society of Hematology (ASH) meeting
    • 14 January 2021
  • Highlights of 2020 San Antonio Breast Cancer Symposium
    • 28 December 2020
Newsletter

Don't miss our newsletter

Would you like to receive our bimonthly e-newsletter with the latest news from Cancer World magazine?

Subscribe now
Social

Would you follow us ?

Contents
  • Interview to Christian Rolfo
    Liquid biopsy for early stage lung cancer moves closer
    • 12 January 2021
  • A 360° approach to a 360° problem: why a mission is the right approach to solving cancer
    • 2 December 2020
  • The cost of cancer in Europe
    • 16 November 2020
MENU
  • About the Journal
    • Editorial Team
    • Leadership and Management
    • Journal staff
    • Events
    • Magazine
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
    • Partnership
    • Supported contents
  • Media Corner
    • Journalist Cancer Guide
    • Cancer Journalism Award
    • Cancer Journalist Grant
Cancer World Magazine
  • About the Journal
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy
Archivio Cancerworld

Input your search keywords and press Enter.